{"id":383095,"date":"2020-11-17T09:25:16","date_gmt":"2020-11-17T14:25:16","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=383095"},"modified":"2020-11-17T09:25:16","modified_gmt":"2020-11-17T14:25:16","slug":"infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\/","title":{"rendered":"Infinity Pharmaceuticals Announces Presentations at the 2020 San Antonio Breast Cancer Symposium"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Infinity Pharmaceuticals Announces Presentations at the 2020 San Antonio Breast Cancer Symposium<\/b><\/p>\n<p>CAMBRIDGE, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.infi.com%2F&amp;esheet=52329461&amp;newsitemid=20201117005874&amp;lan=en-US&amp;anchor=Infinity+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=ecc9a1ea0b85fc00e0c734095ccada83\">Infinity Pharmaceuticals, Inc.<\/a> (NASDAQ: INFI) today announced two poster presentations featuring clinical data from ongoing studies evaluating eganelisib in triple negative breast cancer (TNBC) at the upcoming San Antonio Breast Cancer Symposium (SABCS) being held virtually, December 8-11, 2020.\n<\/p>\n<p><b><span class=\"bwuline\">Presentation Details:<\/span><\/b><\/p>\n<p><b>Title:<\/b> MARIO-3 phase II study initial data evaluating a novel triplet combination of eganelisib (IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC)<br \/>\n<br \/><b>Presenter: <\/b>Erika Hamilton, M.D., Tennessee Oncology<br \/>\n<br \/><b>Date:<\/b> Wednesday, December 9, 2020, 8:00 a.m. CT<br \/>\n<br \/><b>Abstract:<\/b> PS11-32<br \/>\n<br \/><b>Poster Session:<\/b> 11\n<\/p>\n<p><b>Title:<\/b> ARC-2: Efficacy and safety of etrumadenant (AB928) + pegylated liposomal doxorubicin (PLD) \u00b1 eganelisib (IPI-549) in participants with metastatic ovarian and triple negative breast cancer<br \/>\n<br \/><b>Date:<\/b> Wednesday, December 9, 2020, 8:00 a.m. CT<br \/>\n<br \/><b>Abstract:<\/b> PS12-12<br \/>\n<br \/><b>Poster Session:<\/b> 12\n<\/p>\n<p><b>About Infinity and Eganelisib <\/b><\/p>\n<p>\nInfinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing eganelisib, a first-in-class, oral immuno-oncology development candidate that selectively inhibits PI3K-gamma, in multiple clinical studies. MARIO-275 is a global, randomized, controlled combination study of eganelisib combined with Opdivo<sup>\u00ae<\/sup> in I\/O na\u00efve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq<sup>\u00ae<\/sup> and Abraxane<sup>\u00ae<\/sup> in front-line TNBC and in combination with Tecentriq and Avastin<sup>\u00ae<\/sup> in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus AB928 (dual adenosine receptor antagonist) plus Doxil<sup>\u00ae<\/sup> in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1\/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I\/O-na\u00efve, and front-line settings. For more information on Infinity, please refer to Infinity&#8217;s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.infi.com%2F&amp;esheet=52329461&amp;newsitemid=20201117005874&amp;lan=en-US&amp;anchor=www.infi.com&amp;index=2&amp;md5=a127f8bf3adc08d247a0544997691e71\">www.infi.com<\/a>.\n<\/p>\n<p><b>Cautionary Note Regarding Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including those statements regarding plans to participate in presentations at SABCS. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company&#8217;s current expectations, including those factors, risks and uncertainties described under the caption &#8220;Risk Factors&#8221; included in Infinity&#8217;s annual report and quarterly reports filed with the Securities and Exchange Commission (SEC), and in other filings that Infinity makes with the SEC, available through the Company\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.infi.com%2F&amp;esheet=52329461&amp;newsitemid=20201117005874&amp;lan=en-US&amp;anchor=www.infi.com&amp;index=3&amp;md5=fb9a32328f10a0c85ebd60b2c1cb2238\">www.infi.com<\/a>. Any forward-looking statements contained in this press release speak only as of the date hereof, and Infinity does not undertake and expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.\n<\/p>\n<p>\nOpdivo<sup>\u00ae<\/sup> is a registered trademark of Bristol Myers Squibb.<br \/>\n<br \/>Tecentriq<sup>\u00ae<\/sup> is a registered trademark of Genentech, Inc.<br \/>\n<br \/>Abraxane<sup>\u00ae<\/sup> is a registered trademark of Celgene.<br \/>\n<br \/>Doxil<sup>\u00ae<\/sup> is a registered trademark of Janssen Products.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201117005874r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201117005874\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201117005874\/en\/<\/a><\/span><\/p>\n<p>\nAshley Robinson<br \/>\n<br \/>LifeSci Advisors, LLC<br \/>\n<br \/>617-775-5956\n<\/p>\n<p><b>KEYWORDS:<\/b> Texas Massachusetts United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Infinity Pharmaceuticals Announces Presentations at the 2020 San Antonio Breast Cancer Symposium CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced two poster presentations featuring clinical data from ongoing studies evaluating eganelisib in triple negative breast cancer (TNBC) at the upcoming San Antonio Breast Cancer Symposium (SABCS) being held virtually, December 8-11, 2020. Presentation Details: Title: MARIO-3 phase II study initial data evaluating a novel triplet combination of eganelisib (IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC) Presenter: Erika Hamilton, M.D., Tennessee Oncology Date: Wednesday, December 9, 2020, 8:00 a.m. CT Abstract: PS11-32 Poster Session: 11 Title: ARC-2: Efficacy and safety of etrumadenant (AB928) + pegylated liposomal doxorubicin (PLD) &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Infinity Pharmaceuticals Announces Presentations at the 2020 San Antonio Breast Cancer Symposium&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-383095","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Infinity Pharmaceuticals Announces Presentations at the 2020 San Antonio Breast Cancer Symposium - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Infinity Pharmaceuticals Announces Presentations at the 2020 San Antonio Breast Cancer Symposium - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Infinity Pharmaceuticals Announces Presentations at the 2020 San Antonio Breast Cancer Symposium CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced two poster presentations featuring clinical data from ongoing studies evaluating eganelisib in triple negative breast cancer (TNBC) at the upcoming San Antonio Breast Cancer Symposium (SABCS) being held virtually, December 8-11, 2020. Presentation Details: Title: MARIO-3 phase II study initial data evaluating a novel triplet combination of eganelisib (IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC) Presenter: Erika Hamilton, M.D., Tennessee Oncology Date: Wednesday, December 9, 2020, 8:00 a.m. CT Abstract: PS11-32 Poster Session: 11 Title: ARC-2: Efficacy and safety of etrumadenant (AB928) + pegylated liposomal doxorubicin (PLD) &hellip; Continue reading &quot;Infinity Pharmaceuticals Announces Presentations at the 2020 San Antonio Breast Cancer Symposium&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-17T14:25:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201117005874r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Infinity Pharmaceuticals Announces Presentations at the 2020 San Antonio Breast Cancer Symposium\",\"datePublished\":\"2020-11-17T14:25:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\\\/\"},\"wordCount\":553,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201117005874r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\\\/\",\"name\":\"Infinity Pharmaceuticals Announces Presentations at the 2020 San Antonio Breast Cancer Symposium - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201117005874r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-11-17T14:25:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201117005874r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201117005874r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infinity Pharmaceuticals Announces Presentations at the 2020 San Antonio Breast Cancer Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Infinity Pharmaceuticals Announces Presentations at the 2020 San Antonio Breast Cancer Symposium - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\/","og_locale":"en_US","og_type":"article","og_title":"Infinity Pharmaceuticals Announces Presentations at the 2020 San Antonio Breast Cancer Symposium - Market Newsdesk","og_description":"Infinity Pharmaceuticals Announces Presentations at the 2020 San Antonio Breast Cancer Symposium CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced two poster presentations featuring clinical data from ongoing studies evaluating eganelisib in triple negative breast cancer (TNBC) at the upcoming San Antonio Breast Cancer Symposium (SABCS) being held virtually, December 8-11, 2020. Presentation Details: Title: MARIO-3 phase II study initial data evaluating a novel triplet combination of eganelisib (IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC) Presenter: Erika Hamilton, M.D., Tennessee Oncology Date: Wednesday, December 9, 2020, 8:00 a.m. CT Abstract: PS11-32 Poster Session: 11 Title: ARC-2: Efficacy and safety of etrumadenant (AB928) + pegylated liposomal doxorubicin (PLD) &hellip; Continue reading \"Infinity Pharmaceuticals Announces Presentations at the 2020 San Antonio Breast Cancer Symposium\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-17T14:25:16+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201117005874r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Infinity Pharmaceuticals Announces Presentations at the 2020 San Antonio Breast Cancer Symposium","datePublished":"2020-11-17T14:25:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\/"},"wordCount":553,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201117005874r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\/","name":"Infinity Pharmaceuticals Announces Presentations at the 2020 San Antonio Breast Cancer Symposium - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201117005874r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-11-17T14:25:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201117005874r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201117005874r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-presentations-at-the-2020-san-antonio-breast-cancer-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Infinity Pharmaceuticals Announces Presentations at the 2020 San Antonio Breast Cancer Symposium"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/383095","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=383095"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/383095\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=383095"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=383095"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=383095"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}